HMG-CoA reductase is inhibited by:
**Core Concept**
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase is a key enzyme in the mevalonate pathway, responsible for converting HMG-CoA to mevalonate, a precursor for cholesterol synthesis. Inhibiting this enzyme reduces the production of cholesterol in the liver.
**Why the Correct Answer is Right**
Statins, a class of lipid-lowering medications, specifically inhibit HMG-CoA reductase. This enzyme is a target for statins because it is a crucial step in the cholesterol biosynthesis pathway. By blocking HMG-CoA reductase, statins decrease the liver's ability to produce cholesterol, thereby reducing the amount of low-density lipoprotein (LDL) cholesterol in the blood.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not specified, so we cannot evaluate its correctness.
* **Option B:** While atorvastatin is a statin, the question asks for the enzyme inhibited by statins in general, not a specific statin medication.
* **Option C:** This option is not specified, so we cannot evaluate its correctness.
* **Option D:** This option is not specified, so we cannot evaluate its correctness.
**Clinical Pearl / High-Yield Fact**
Statins, by inhibiting HMG-CoA reductase, not only lower LDL cholesterol but also have pleiotropic effects, including anti-inflammatory properties and improvement in endothelial function.
**Correct Answer:** A. Statins.